Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes - Trial NCT03015220
Access comprehensive clinical trial information for NCT03015220 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 458 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 3
Jan 10, 2017
Jul 12, 2018
Primary Outcome
Number of Treatment-emergent Adverse Events (TEAEs)
Summary
This trial is conducted in Asia. The aim of this trial is to investigate Safety and efficacy
 of oral semaglutide versus dulaglutide both in combination with one OAD (oral antidiabetic
 drug) in Japanese subjects with type 2 diabetes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03015220
Non-Device Trial